FDA approves new treatment for a type of late-stage lung cancer

The U.S. Food and Drug Administration has approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer whose tumors express specific types of epidermal growth factor receptor gene mutations, as detected by an FDA-approved test. Gilotrif is a tyrosine kinase inhibitor that blocks proteins that promote the development of cancerous cells. Read more here.